Devon Evans, MD
Hematology & Oncology · Westbrook, MENPI 1518183532
Payments from drug & device makers
Across 153 payments — averaging $1623.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$202K
- AstraZeneca$27K
- Mirati Therapeutics, Inc.$12K
- Bayer$3K
- Reflexion Medical, Inc.$2K
- Genentech, Inc.$455
- plus $2K from 34 others
What the payments were for
- Consulting fees$18,59360%
- Speaking & faculty fees$8,00026%
- Travel & lodging$2,3307%
- Food & beverage$2,1927%
- Education$710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 36 | $201,933 |
| AstraZeneca | 33 | $27,296 |
| Mirati Therapeutics, Inc. | 2 | $11,707 |
| Bayer | 2 | $3,100 |
| Reflexion Medical, Inc. | 4 | $2,160 |
| Genentech, Inc. | 2 | $455 |
| Johnson & Johnson(2 entities) | 9 | $217 |
| Daiichi Sankyo Inc. | 8 | $194 |
| Pharmacyclics LLC, An Abbvie Company | 8 | $186 |
| AbbVie | 7 | $176 |
| Boston Scientific | 1 | $116 |
| Novartis | 4 | $71 |
| ASD Specialty Healthcare, LLC | 1 | $56 |
| Pfizer | 3 | $50 |
| E.r. Squibb & Sons, L.L.C. | 2 | $48 |
| Astellas Pharma US Inc | 2 | $47 |
| Incyte Corporation | 2 | $44 |
| Novocure Inc. | 1 | $41 |
| Rigel Pharmaceuticals, Inc. | 2 | $40 |
| Seagen Inc. | 2 | $32 |
| Lilly USA, LLC | 2 | $27 |
| Exelixis Inc. | 2 | $26 |
| Amgen | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Sobi, Inc | 1 | $21 |
| Beone Medicines USA, Inc. | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Dova Pharmaceuticals | 1 | $20 |
| Eisai Inc. | 1 | $19 |
| Caris MPI, Inc. | 1 | $19 |
| Tolmar, Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| EMD Serono, Inc. | 1 | $15 |
| ADC Therapeutics America, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Acrotech Biopharma Inc. | 1 | $13 |
| Bristol Myers Squibb | 1 | $12 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$17,620
- TAGRISSO$9,142
- REFLEXION MEDICAL RADIOTHERAPY SYSTEM$2,093
- AXIOS$116
How this compares
$248,343 in reported general payments places this provider in the 85th percentile of 60 hematology & oncology providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 51 | $807,635 |
| ErleadaApalutamide | 42 | $623,329 |
| PomalystPomalidomide | 29 | $518,898 |
| VerzenioAbemaciclib | 31 | $496,830 |
| TepmetkoTepotinib Hcl | 18 | $442,787 |
| ImbruvicaIbrutinib | 26 | $423,363 |
| Darzalex FasproDaratumumab-Hyaluronidase-Fihj | 43 | $402,607 |
| TagrissoOsimertinib Mesylate | 20 | $344,700 |
| BrukinsaZanubrutinib | 21 | $314,571 |
| JaypircaPirtobrutinib | 11 | $226,471 |
| Lenalidomide | 15 | $218,421 |
| XermeloTelotristat Etiprate | 21 | $203,208 |
| JakafiRuxolitinib Phosphate | 11 | $181,489 |
| AlecensaAlectinib Hcl | 11 | $177,523 |
| XtandiEnzalutamide | 12 | $169,958 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $12 | $807,63551 claims |
| Lilly USA, LLCVerzenio, Jaypirca | $27 | $723,30142 claims |
| Johnson & JohnsonErleada, Xarelto | $217 | $640,77064 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $48 | $620,74946 claims |
| EMD Serono, Inc.Tepmetko | $15 | $442,78718 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $186 | $423,36326 claims |
| AstraZenecaTagrisso | $27,296 | $344,70020 claims |
| Incyte CorporationJakafi | $44 | $181,48911 claims |
| Genentech USA, Inc.Alecensa | $18 | $177,52311 claims |
| Astellas Pharma US IncXtandi | $47 | $169,95812 claims |
| AbbVieCreon | $176 | $84,59031 claims |
| PfizerEliquis | $50 | $23,11427 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 60 hematology & oncology providers in Maine.
Other hematology & oncology in Westbrook
- Christian ThomasWestbrook$4.7M
- Chiara BattelliWestbrook$1.5M
- Matthew DuganWestbrook$675K
- John WintersWestbrook$341K
- Eleni NackosWestbrook$217K
- Tracey WeisbergWestbrook$109K
- Daniel RauschWestbrook$104K
- Patrick BolandWestbrook$20K
- Owen PickusWestbrook$1K
- Anna NiegowskaPortland$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.